Hypertension Channel
Topics
Medications
Quicklinks
Related Channels

Common and Rare Reactions to Lisinopril-Hydrochlorothiazide

Common Side Effects of Lisinopril-Hydrochlorothiazide

Lisinopril-hydrochlorothiazide has been studied extensively in clinical trials for people with high blood pressure. Before medicines are approved, they must go through several clinical studies, where many people are given a particular medicine and are then compared to a group of people not given the medicine. In these studies, the side effects are always documented. As a result, it is possible to see what side effects occur, how often they appear, and how they compare to the group not taking the medicine. In these studies, the most common lisinopril-hydrochlorothiazide side effects included:
 
  • Dizziness -- in up to 7.5 percent of people
  • Headache -- up to 5.2 percent
  • Cough -- up to 3.9 percent
  • Fatigue -- up to 3.7 percent
  • Dizziness, lightheadedness, or fainting on standing from a sitting or lying down position (known medically as orthostatic effects) -- up to 3.2 percent.
     
Other side effects (occurring in more than 1 percent of people) include but are not limited to:
 

Rare Side Effects Seen With Lisinopril-Hydrochlorothiazide

Rare lisinopril-hydrochlorothiazide side effects occur in less than 1 percent of people taking the drug. Because these side effects are so uncommon, it is often difficult to tell whether they are actually caused by the medication or something else.
 
Some of these less common side effects include but are not limited to:
 
Life After a Stent: 5 Realistic Ways to Take Charge of Your Health

Lisinopril-Hydrochlorothiazide Drug

Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.